HIM
VIR icon

Hillsdale Investment Management’s Vir Biotechnology VIR Stock Holding History

Hillsdale Investment Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
187,196
+26,100
+16% +$248K 0.04% 312
2026
Q1 		$1.44M Buy
+161,096
New +$1.28M 0.04% 323

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Hillsdale Investment Management's VIR Position: Q2 2026 in Review

Hillsdale Investment Management increased its Vir Biotechnology (VIR) stake by 16% in Q2 2026, buying an estimated $248K and bringing the position to 187,196 shares worth $1.91M. The position accounts for 0.04% of the portfolio, ranked #312.

Hillsdale Investment Management first reported a position in VIR in Q1 2026 and has held it in 2 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Hillsdale Investment Management held 187,196 shares of Vir Biotechnology worth $1.91M as of Q2 2026.
  • Hillsdale Investment Management bought 26,100 Vir Biotechnology shares in Q2 2026, an estimated $248K.
  • Vir Biotechnology made up 0.04% of Hillsdale Investment Management's portfolio in Q2 2026, its #312 holding.
  • Hillsdale Investment Management first reported a position in Vir Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.